Depressed Colorectal Cancer: A New Paradigm in Early Colorectal Cancer.


Journal

Clinical and translational gastroenterology
ISSN: 2155-384X
Titre abrégé: Clin Transl Gastroenterol
Pays: United States
ID NLM: 101532142

Informations de publication

Date de publication:
12 2020
Historique:
entrez: 29 1 2021
pubmed: 30 1 2021
medline: 16 7 2021
Statut: ppublish

Résumé

In contrast to most colorectal carcinomas arising from pedunculated or sessile protruded adenomas, submucosal-invasive (pT1) colorectal carcinoma exhibiting a depressed surface (hereinafter, "depressed colorectal carcinoma," identified by means of high-definition endoscopy) is considered to be derived from depressed precursors. We hypothesized that depressed colorectal neoplasms have unique clinicopathological features different that are different from those of protruded and flat colorectal neoplasms. We classified 27,129 colorectal neoplasms (909 pT1 carcinomas and 26,220 adenomas) resected between 2001 and 2017 into depressed (211 carcinomas and 109 adenomas), flat (304 carcinomas and 11,246 adenomas), and protruded subtypes (394 carcinomas and 14,865 adenomas) and compared their clinicopathological features. As exploratory analyses of pT1 carcinomas, we conducted whole-exome sequencing for 19 depressed and 8 protruded subtypes and RNA sequencing for 8 depressed and 8 protruded subtypes. pT1 carcinomas were more common in depressed lesions (66%) than in protruded (2.6%) and flat lesions (2.6%) (P < 0.001). Compared with nondepressed pT1 carcinomas, depressed pT1 carcinomas were positively correlated with lymphovascular invasion, tumor budding, and massive submucosal invasion and inversely correlated with the presence of an adenoma component (all P < 0.001). Depressed adenomas were more likely to contain high-grade dysplasia than nondepressed adenomas (49% vs 11%, P < 0.001). A KRAS mutation was observed only in one of the 19 depressed pT1 carcinomas. Relative to protruded carcinomas, depressed carcinomas generally exhibited higher expression of genes related to angiogenesis and epithelial-mesenchymal transition. Depressed colorectal neoplasms may harbor a unique combination of malignant histopathological phenotypes and molecular features.

Identifiants

pubmed: 33512809
doi: 10.14309/ctg.0000000000000269
pii: 01720094-202012000-00017
pmc: PMC7732270
doi:

Substances chimiques

Biomarkers, Tumor 0
KRAS protein, human 0
Proto-Oncogene Proteins p21(ras) EC 3.6.5.2

Types de publication

Journal Article Observational Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e00269

Subventions

Organisme : NCI NIH HHS
ID : R35 CA197735
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA230873
Pays : United States

Références

Oncol Rep. 2013 Jul;30(1):350-6
pubmed: 23673484
Genome Res. 2018 Aug;28(8):1111-1125
pubmed: 30012835
Hum Pathol. 1996 Oct;27(10):1042-9
pubmed: 8892588
Gastroenterology. 2017 Sep;153(3):732-742.e1
pubmed: 28583826
Gut. 2011 Mar;60(3):397-411
pubmed: 21036793
N Engl J Med. 2013 Sep 19;369(12):1095-105
pubmed: 24047059
Gut. 2000 Aug;47(2):251-5
pubmed: 10896917
Nat Rev Cancer. 2009 Apr;9(4):265-73
pubmed: 19262571
Nat Rev Cancer. 2017 Feb;17(2):79-92
pubmed: 28050011
Gastroenterology. 2006 Feb;130(2):566-76; quiz 588-9
pubmed: 16472608
Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
Endosc Int Open. 2017 Dec;5(12):E1284-E1288
pubmed: 29218321
Endoscopy. 1993 Sep;25(7):455-61
pubmed: 8261988
Gastrointest Endosc. 2008 Oct;68(4 Suppl):S3-47
pubmed: 18805238
Nat Med. 2015 Nov;21(11):1350-6
pubmed: 26457759
J Gastroenterol Hepatol. 2000 Mar;15 Suppl:D66-70
pubmed: 10759223
Gastrointest Endosc. 2003 Dec;58(6 Suppl):S3-43
pubmed: 14652541
Clin Gastroenterol Hepatol. 2005 Jul;3(7 Suppl 1):S33-6
pubmed: 16012993
Nat Biotechnol. 2010 May;28(5):511-5
pubmed: 20436464
Nature. 2014 Jan 23;505(7484):495-501
pubmed: 24390350
Gastroenterology. 2004 Aug;127(2):385-94
pubmed: 15300569
Int J Colorectal Dis. 2018 Aug;33(8):1029-1038
pubmed: 29748707
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Dig Endosc. 2015 Mar;27(3):300-2
pubmed: 25754006
Dig Endosc. 2015 May;27(4):417-434
pubmed: 25652022
Endoscopy. 1995 Jan;27(1):54-7; discussion 61
pubmed: 7601037
JAMA. 2008 Mar 5;299(9):1027-35
pubmed: 18319413
Methods Mol Biol. 2014;1150:45-79
pubmed: 24743990
Ann Pathol. 2011 Nov;31(5 Suppl):S27-31
pubmed: 22054452
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
Genome Biol. 2011 Aug 11;12(8):R72
pubmed: 21835007
N Engl J Med. 1993 Dec 30;329(27):1977-81
pubmed: 8247072
Int J Clin Oncol. 2018 Feb;23(1):1-34
pubmed: 28349281

Auteurs

Shin-Ei Kudo (SE)

Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan.

Yuta Kouyama (Y)

Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan.
Kyushu University Beppu Hospital, Beppu, Japan.

Yushi Ogawa (Y)

Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan.
Kyushu University Beppu Hospital, Beppu, Japan.

Katsuro Ichimasa (K)

Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan.

Tsuyoshi Hamada (T)

Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Kazuki Kato (K)

Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan.
Kyushu University Beppu Hospital, Beppu, Japan.

Koki Kudo (K)

Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan.
Kyushu University Beppu Hospital, Beppu, Japan.

Takaaki Masuda (T)

Kyushu University Beppu Hospital, Beppu, Japan.

Hajime Otsu (H)

Kyushu University Beppu Hospital, Beppu, Japan.

Masashi Misawa (M)

Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan.

Yuichi Mori (Y)

Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan.

Toyoki Kudo (T)

Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan.

Takemasa Hayashi (T)

Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan.

Kunihiko Wakamura (K)

Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan.

Hideyuki Miyachi (H)

Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan.

Naruhiko Sawada (N)

Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan.

Toshiro Sato (T)

Department of Gastroenterology, Keio University School of Medicine, Tokyo, Japan.

Tatsuhiro Shibata (T)

Division of Cancer Genomics, National Cancer Center Research Institute and Laboratory of Molecular Medicine, Tokyo, Japan.

Shigeharu Hamatani (S)

Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan.
Department of Pathology, The Jilei University School of Medicine, Tokyo, Japan.

Tetsuo Nemoto (T)

Department of Pathology, Showa University Northern Yokohama Hospital, Yokohama, Japan.

Fumio Ishida (F)

Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan.

Atsushi Niida (A)

Department of Pathology, The Jilei University School of Medicine, Tokyo, Japan.

Satoru Miyano (S)

Division of Health Medical Computational Science, Health Intelligence Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Masanobu Oshima (M)

Division of Genetics, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.

Shuji Ogino (S)

Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA.
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Cancer Immunology and Cancer Epidemiology Programs, Dana-Farber Harvard Cancer Center, Boston, Massachusetts, USA.
Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.

Koshi Mimori (K)

Kyushu University Beppu Hospital, Beppu, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH